| Online-Ressource |
Verfasst von: | Penack, Olaf [VerfasserIn]  |
| Peczynski, Christophe [VerfasserIn]  |
| Koenecke, Christian [VerfasserIn]  |
| Polge, Emmanuelle [VerfasserIn]  |
| Sanderson, Robin [VerfasserIn]  |
| Yakoub-Agha, Ibrahim [VerfasserIn]  |
| Fegueux, Nathalie [VerfasserIn]  |
| Daskalakis, Michael [VerfasserIn]  |
| Collin, Matthew [VerfasserIn]  |
| Dreger, Peter [VerfasserIn]  |
| Kröger, Nicolaus [VerfasserIn]  |
| Schanz, Urs [VerfasserIn]  |
| Bloor, Adrian [VerfasserIn]  |
| Ganser, Arnold [VerfasserIn]  |
| Besley, Caroline [VerfasserIn]  |
| Wulf, Gerald G. [VerfasserIn]  |
| Novak, Urban [VerfasserIn]  |
| Moiseev, Ivan [VerfasserIn]  |
| Schoemans, Hélène [VerfasserIn]  |
| Basak, Grzegorz W. [VerfasserIn]  |
| Chabannon, Christian [VerfasserIn]  |
| Sureda, Anna [VerfasserIn]  |
| Glass, Bertram [VerfasserIn]  |
| Peric, Zinaida [VerfasserIn]  |
Titel: | Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma |
Titelzusatz: | a retrospective study from the EBMT transplant complications and lymphoma working party |
Verf.angabe: | Olaf Penack, Christophe Peczynski, Christian Koenecke, Emmanuelle Polge, Robin Sanderson, Ibrahim Yakoub-Agha, Nathalie Fegueux, Michael Daskalakis, Matthew Collin, Peter Dreger, Nicolaus Kröger, Urs Schanz, Adrian Bloor, Arnold Ganser, Caroline Besley, Gerald G. Wulf, Urban Novak, Ivan Moiseev, Hélène Schoemans, Grzegorz W. Basak, Christian Chabannon, Anna Sureda, Bertram Glass and Zinaida Peric |
E-Jahr: | 2023 |
Jahr: | 27 September 2023 |
Umfang: | 10 S. |
Fussnoten: | Gesehen am 22.01.2024 |
Titel Quelle: | Enthalten in: Frontiers in immunology |
Ort Quelle: | Lausanne : Frontiers Media, 2010 |
Jahr Quelle: | 2023 |
Band/Heft Quelle: | 14(2023), Artikel-ID 1252811, Seite 1-10 |
ISSN Quelle: | 1664-3224 |
Abstract: | We investigated ≥ grade 3 (CTC-AE) organ toxicities for commercial CD19 chimeric antigen receptor T cell (CAR-T cell) products in 492 patients (Axi-Cel; n = 315; Tisa-Cel; n = 177) with Large B-cell Lymphoma in the European Society for Blood and Marrow Transplantation (EBMT) CAR-T registry. The incidence of ≥ grade 3 organ toxicities during the first 100 days after CAR-T was low and the most frequent were: renal (3.0%), cardiac (2.3%), gastro-intestinal (2.3%) and hepatic (1.8%). The majority occurred within three weeks after CAR-T cell therapy. Overall survival was 83.1% [79.8-86.5; 95% CI] at 3 months and 53.5% [49-58.4; 95% CI] at one year after CAR-T. The most frequent cause of death was tumour progression (85.1%). Non-relapse mortality was 3.1% [2.3-4.1; 95% CI] at 3 months and 5.2% [4.1-6.5; 95% CI] at one year after CAR-T. The most frequent causes of non-relapse mortality were cell-therapy-related toxicities including organ toxicities (6.4% of total deaths) and infections (4.4% of total deaths). Our data demonstrates good safety in the European real-world setting. |
DOI: | doi:10.3389/fimmu.2023.1252811 |
URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://www.frontiersin.org/articles/10.3389/fimmu.2023.1252811 |
| DOI: https://doi.org/10.3389/fimmu.2023.1252811 |
Datenträger: | Online-Ressource |
Sprache: | eng |
K10plus-PPN: | 1878612379 |
Verknüpfungen: | → Zeitschrift |
Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma / Penack, Olaf [VerfasserIn]; 27 September 2023 (Online-Ressource)